GLP1R and obesity due to melanocortin 4 receptor deficiency: Since the discovery and functional verification of GLP-1 in the 1980s (Kreymann et al., 1987), it has markedly reshaped current clinical approaches to the treatment of obesity and type 2 diabetes, providing superior glycemic control with reduced hypoglycemic risks compared to conventional therapies.